Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital.
The aim of this study was to determine the 60-day all-cause mortality rate, during chemotherapy, for patients with oesophagogastric, pancreatic, and colorectal cancer. We analysed 1720 patients that were treated within randomised trials. The minimum follow-up period was > 60 days. Sixty-day mortality and 95% Confidence Intervals (CI) were calculated from the Kaplan-Meier survival curves. Causes of death were classified as treatment-related, disease-related or vascular syndrome-induced deaths. Patients with oesophagogastric cancer that could not tolerate a cis-platinum-containing regimens were treated with infused 5-fluorouracil (5FU)+/-mitomycin-C (MMC). The 60-day mortality rate depends upon the site of the primary tumour and the disease status (adjuvant versus advanced). The rate of treatment- and vascular syndrome-induced deaths was </=1.8%. For patients with advanced disease, most of the early deaths were disease-related. In adjuvant colorectal cancer, one patient died within 60 days (myocardial infarction). This study provides a benchmark for assessing the safety of regimens used in these disease settings.